Title: Binifibrate
CAS Registry Number: 69047-39-8
CAS Name: 3-Pyridinecarboxylic acid 2-[2-(4-chlorophenoxy)-2-methyl-1-oxopropoxy]-1,3-propanediyl ester
Additional Names: trihydroxypropane 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate; 2-(p-chlorophenoxy)-2-methylpropionic acid ester with 1,3-dinicotinoyloxy-2-propanol; glyceryl 2-p-chlorophenoxyisobutyrate-1,3-dinicotinate
Manufacturers' Codes: WAC-104
Trademarks: Biniwas (Wassermann)
Molecular Formula: C25H23ClN2O7
Molecular Weight: 498.91
Percent Composition: C 60.18%, H 4.65%, Cl 7.11%, N 5.61%, O 22.45%
Literature References: Antilipemic agent structurally related to clofibrate, q.v. Prepn: R. Andreoli, X. Cicera, ES 463218 (1978 to Soc. Espan. Espec. Farm.-Ter.), C.A. 90, 72067h (1979); and pharmacology: eidem, BE 884722 (1980 to Soc. Espan. Espec. Farm.-Ter.). Microhemorheological properties in animals: L. Bruseghini et al., Arzneim.-Forsch. 33, 854 (1983); in patients: M. Dalmau et al., ibid. 858. Clinical evaluation: M. Labios et al., Clin. Hemorheol. Microcirc. 21, 79 (1999).
Properties: Yellowish-white crystals from alcohol-isopropyl ether, mp 100°. Saponification number 166. LD50 orally in mice and rats: >4000 mg/kg (Andreoli).
Melting point: mp 100°
Toxicity data: LD50 orally in mice and rats: >4000 mg/kg (Andreoli)
Therap-Cat: Antilipemic.
Keywords: Antilipemic; Fibrates.

Others monographs:
Manganese Oleate1,2:5,6-DibenzanthraceneNifenalolDorzolamide
DapoxetineBarium NitriteCentauryFerrous Sulfate
DisulfotonMuramyl DipeptideConjugated EstrogensEtiroxate
IsegananCarbon NitrideEtomidatePiromen
©2016 DrugLead US FDA&EMEA